Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 37 Issue 3
. 
Turn off MathJax
Article Contents
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2019  >  37(3): 268-273

LINLili, ZHANG Yan, LIU Zhihong, WU Jue, SONG Hongtao. The effect of clostridium butyricum enterococcus triple viable tablet on GP regimen in advanced NSCLC patients[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(3): 268-273. doi: 10.3969/j.issn.1006-0111.2019.03.016
Citation: LINLili, ZHANG Yan, LIU Zhihong, WU Jue, SONG Hongtao. The effect of clostridium butyricum enterococcus triple viable tablet on GP regimen in advanced NSCLC patients[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(3): 268-273. doi: 10.3969/j.issn.1006-0111.2019.03.016
shu

The effect of clostridium butyricum enterococcus triple viable tablet on GP regimen in advanced NSCLC patients

doi: 10.3969/j.issn.1006-0111.2019.03.016
  • 1.

    Department of Pharmacy, No. 900 Hospital of Joint Logistics Units, Fuzhou 350025, China

  • 2.

    Department of Oncology, No. 900 Hospital of Joint Logistics Units, Fuzhou 350025, China

  • Received Date: 2018-11-25
  • Rev Recd Date: 2019-03-05
  • Objective To explore the effect of clostridium butyricum enterococcus triple viable tablet on the efficacy and adverse reactions of gemcitabine plus platinum(GP) regimen for the patients with advanced non-small cell lung cancer(NSCLC). Methods The records of 78 NSCLC patients who treated with GP regimen as first-line palliative chemotherapy were reviewed,and the related data were recorded.Statistical analyses were performed with SPSS 25.0. Results Compared with the control group,the probiotic preparation group showed a significant difference in disease control rate and progression-free survival (P value are 0.048 and 0.012 respectively),while there were no significant differences in objective response rate and the risk of adverse reaction events(P>0.05). Conclusion The clostridium butyricum enterococcus triple viable tablet might improve the efficacy of GP regimen as a first-line palliative chemotherapy for advanced NSCLC patients.
  • [1] LEDERBERG J.Infectious history[J].Science,2000,288(5464):287-293.
    [2] GILLS R,POP M,DEBOY R T,et al. Metagenomic analysis of the human distal gut microbiome[J].Science,2006,312(5778):1355-1359.
    [3] O'HARAA M,SHANAHAN F.The gut flora as a forgotten organ[J].EMBO Rep,2006,7(7):688-693.
    [4] POPEJ L,TOMKOVICH S,YANG Y,et al. Microbiota as a mediator of cancer progression and therapy[J].Transl Res,2017,179:139-154.
    [5] FUHRMANB J,FEIGELSON H S,FLORES R,et al. Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women[J].J Clin Endocrinol Metab,2014,99(12):4632-4640.
    [6] PRAGMANA A,KIM H B,REILLY C S,et al. The lung microbiome in moderate and severe chronic obstructive pulmonary disease[J].PLoS One,2012,7(10):e47305.
    [7] SCHWABER F,JOBIN C.The microbiome and cancer[J].Nat Rev Cancer,2013,13(11):800-812.
    [8] ZACKULARJ P,BAXTER N T,IVERSON K D,et al. The gut microbiome modulates colon tumorigenesis[J].mBio,2013,4(6):e613-e692.
    [9] ⅡDA N,DZUTSEV A,STEWARTC A,et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment[J].Science,2013,342(6161):967-970.
    [10] PEREZ-CHANONA E,TRINCHIERI G.The role of microbiota in cancer therapy[J].Curr Opin Immunol,2016,39:75-81.
    [11] VIAUD S,SACCHERI F,MIGNOT G,et al. Theintestinal microbiota modulates the anticancer immune effects of cyclophosphamide[J].Science,2013,342(6161):971-976.[LinkOut]
    [12] ZITVOGEL L,GALLUZZI L,VIAUD S,et al. Cancer and the gut microbiota:an unexpected link[J].SciTransl Med,2015,7(271):271ps1.
    [13] CRONIN K A,LAKE A J,SCOTT S,et al. Annual report to the Nation on the status of cancer,part I:national cancer statistics[J].Cancer,2018,124(13):2785-2800.
    [14] YE T,PAN Y,WANG R,et al. Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old[J].J Thorac Dis,2014,6(10):1396-1402.
    [15] SCHILLER J H,HARRINGTON D,BELANI C P,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med,2002,346(2):92-98.
    [16] VANDEVOORDE J,BALZARINI J,LIEKENS S.An emerging understanding of the Janus face of the human microbiome:enhancement versus impairment of cancer therapy[J].J Antimicrob Chemother,2014,69(10):2878-2880.
    [17] GELLERL T,BARZILY-ROKNI M,DANINO T,et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine[J].Science,2017,357(6356):1156-1160.
    [18] GUI Q F,LU H F,ZHANG C X,et al. Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model[J].Genet Mol Res,2015,14(2):5642-5651.
    [19] PALA V,SIERI S,BERRINO F,et al. Yogurt consumption and risk of colorectal cancer in the Italian European prospective investigation into cancer and nutrition cohort[J].Int J Cancer,2011,129(11):2712-2719.
    [20] 许春进,韩敏,徐峰,等.化疗药物对胃癌患者肠道菌群谱的影响及益生菌干预作用的临床研究[J].中华消化病与影像杂志(电子版),2016,6(4):154-159.
    [21] STEIN A,VOIGT W,JORDAN K.Chemotherapy-induced diarrhea:pathophysiology,frequency and guideline-based management[J].Ther Adv Med Oncol,2010,2(1):51-63.
    [22] 陈晓慧.肺癌患者铂类药物化疗前后肠道菌群变化的相关研究[D].大连:大连医科大学,2016.
    [23] 刘远预.含铂双药化疗对非小细胞肺癌患者肠道菌群的影响[D].大连:大连医科大学,2017.
    [24] 孙曦.胃癌XELOX、肺癌GP化疗对肠道微生物的影响及口服地衣芽孢杆菌干预的研究[D].北京:中国人民解放军医学院,2016.
    [25] THERASSE P,ARBUCK S,EISENHAUER EA,et al. New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer Institute of the United States,National Cancer Institute of Canada[J].J Natl Cancer Inst,2000,92(3):205-216.
    [26] HUANG Y K,YANG W,LIU H,et al. Effect of high-dose methotrexate chemotherapy on intestinal Bifidobacteria,Lactobacillus and Escherichia coli in children with acute lymphoblastic leukemia[J].Exp Biol Med (Maywood),2012,237(3):305-311.
    [27] STRINGERA M,GIBSON R J,LOGAN R M,et al. Gastrointestinal microflora and mucins may play a critical role in the development of 5-fluorouracil-induced gastrointestinal mucositis[J].Exp Biol Med (Maywood),2009,234(4):430-441.
    [28] LINX B,DIELEMAN L A,KETABI A,et al. Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats[J].PLoS One,2012,7(7):e39764.
    [29] HEMARAJATA P,VERSALOVIC J.Effects of probiotics on gut microbiota:mechanisms of intestinal immunomodulation and neuromodulation[J].Therap Adv Gastroenterol,2013,6(1):39-51.
    [30] 朱亮,虞秋国,乔鹏,等.地衣芽孢杆菌活菌胶囊对不能手术非小细胞肺癌GP化疗致肠道菌落失衡的影响[J].湖南师范大学学报(医学版),2018,15(3):85-87.
    [31] O'FLAHERTY S,SAULNIER D,POT B,et al. How can probiotics and prebiotics impact mucosal immunity?[J].Gut Microbes,2010,1(5):293-300.
    [32] HASSAN H,ROMPOLA M,GLASERA W,et al. Systematic review and meta-analysis investigating the efficacy and safety of probiotics in people with cancer[J].Support Care Cancer,2018,26(8):2503-2509.
    [33] REDMANM G,WARD E J,PHILLIPS R S.The efficacy and safety of probiotics in people with cancer:a systematic review[J].Ann Oncol,2014,25(10):1919-1929.
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(3113) PDF downloads(397) Cited by()

Related
Proportional views

The effect of clostridium butyricum enterococcus triple viable tablet on GP regimen in advanced NSCLC patients

doi: 10.3969/j.issn.1006-0111.2019.03.016
  • 1. Department of Pharmacy, No. 900 Hospital of Joint Logistics Units, Fuzhou 350025, China
  • 2. Department of Oncology, No. 900 Hospital of Joint Logistics Units, Fuzhou 350025, China
  • Received Date: 2018-11-25
  • Rev Recd Date: 2019-03-05

Abstract: Objective To explore the effect of clostridium butyricum enterococcus triple viable tablet on the efficacy and adverse reactions of gemcitabine plus platinum(GP) regimen for the patients with advanced non-small cell lung cancer(NSCLC). Methods The records of 78 NSCLC patients who treated with GP regimen as first-line palliative chemotherapy were reviewed,and the related data were recorded.Statistical analyses were performed with SPSS 25.0. Results Compared with the control group,the probiotic preparation group showed a significant difference in disease control rate and progression-free survival (P value are 0.048 and 0.012 respectively),while there were no significant differences in objective response rate and the risk of adverse reaction events(P>0.05). Conclusion The clostridium butyricum enterococcus triple viable tablet might improve the efficacy of GP regimen as a first-line palliative chemotherapy for advanced NSCLC patients.

LINLili, ZHANG Yan, LIU Zhihong, WU Jue, SONG Hongtao. The effect of clostridium butyricum enterococcus triple viable tablet on GP regimen in advanced NSCLC patients[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(3): 268-273. doi: 10.3969/j.issn.1006-0111.2019.03.016
Citation: LINLili, ZHANG Yan, LIU Zhihong, WU Jue, SONG Hongtao. The effect of clostridium butyricum enterococcus triple viable tablet on GP regimen in advanced NSCLC patients[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(3): 268-273. doi: 10.3969/j.issn.1006-0111.2019.03.016
shu

    HTML

Reference (33)

Catalog

    版权所有：《药学实践与服务》编辑委员会

    Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

    Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return